Jonathan Zalevsky

Dr. Zalevsky has over 15 years of research and discovery experience in large pharmaceutical and biotech. Dr. Zalevsky joined Nektar in 2015 to lead biological and translational research and guide strategy for the Nektar discovery portfolio. Dr. Zalevsky’s expertise in immunology, as well as his experience across biological modalities and therapeutic areas, have helped fuel the growth of the company’s immuno-oncology and immunology pipeline. He led the discovery and preclinical development for NKTR-358 (a T regulatory cell stimulatory agent developed for auto-immune diseases with partner Eli Lilly & Co.) and NKTR-262 (a small molecule TLR agonist developed in combination with NKTR-214). Before joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. At Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development. Before this, Dr. Zalevsky held several research and development positions at Xencor, where he was responsible for the discovery and development of Xencor's first four clinical-stage assets. He received his Ph.D. in Biochemistry from the Tetrad Program at the University of California at San Francisco (UCSF).